Replies to post #118658 on Biotech Values

[jq1234]

Copaxone’s claim to fame has never been stellar efficacy, but rather its modest efficacy and longstanding safety profile, which spans several decades.

I agree completely. People tend to think MS patients and neurologists are eager to switch to new approved MS drugs. That's not true at all in reality. MS drug potential is demonstrated via real life usage, not in clinical trial alone. If you look at clinical trial data alone, you wouldn't think Copaxone would have sale number like it has today.

Medpage Today has very good AAN coverage. It gives good idea how real life practice is like:

http://www.medpagetoday.com/MeetingCoverage/AAN/

Gilenya:

http://www.medpagetoday.com/MeetingCoverage/AAN/25965

[investorgold2002]

was there any studies that compares safety and efficacy of gilenya to copaxone

[DewDiligence]

Re: BG-12 safety record

BIIB’s two fumaric-acid derivates—BG-12 and Fumaderm—are not identical. The difference is that Fumaderm* contains both dimethyl fumarate and monoethyl fumarate, while BG-12 contains dimethyl fumarate only. This distinction probably isn’t consequential from a safety standpoint, but I don’t think one can say for sure.

This post was prompted by an assertion on another board that BG-12 has a longstanding safety record, which is not quite correct.

*Approved in Germany for psoriasis.